| Mrs Suzanne S Cleland Zamudio, MD | |
|
100 E Jackson Ave Ste 102, Ellensburg, WA 98926-3693 | |
| (509) 933-8860 | |
| (509) 933-8870 |
| Full Name | Mrs Suzanne S Cleland Zamudio |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 31 Years |
| Location | 100 E Jackson Ave Ste 102, Ellensburg, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609883768 | NPI | - | NPPES |
| 151216 | Medicaid | OR |
| Facility Name | Location | Facility Type |
|---|---|---|
| Astria Sunnyside Hospital | Sunnyside, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sunnyside Community Hospital Association | 1658280896 | 43 |
News Archive
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced preliminary results from the EnligHTN III study, which found the company's second-generation EnligHTN™ renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. The results were presented during a hot line late-breaking clinical trial session at EuroPCR 2014.
Sistemic Ltd., the recent winners of the coveted Most Promising Life Science Company by Nexxus, today announced the launch of their SistemTOX™ early predictive and investigative drug toxicity screening service. Based on world-leading Scottish microRNA research and technology, SistemTOX™ filters out potentially harmful compounds early in the development process, helping to save millions of pounds in costs.
People with a family history of male breast cancer perceive themselves to be at higher risk of developing the disease than do patients with a family history of female breast cancer; however those with male breast cancer in their families are less likely to know about or seek genetic testing than those with a family history of female breast cancer, according to a study led by researchers at the University of Louisville's James Graham Brown Cancer Center.
Researchers have long questioned why patients with Duchenne muscular dystrophy (DMD) tend to manage well through childhood and adolescence, yet succumb to their disease in early adulthood, or why elderly people who lose muscle strength following bed rest find it difficult or impossible to regain.
› Verified 6 days ago
| Entity Name | Kittitas County Public Hospital Dist 1 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356375307 PECOS PAC ID: 0547179608 Enrollment ID: O20040213000046 |
News Archive
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced preliminary results from the EnligHTN III study, which found the company's second-generation EnligHTN™ renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. The results were presented during a hot line late-breaking clinical trial session at EuroPCR 2014.
Sistemic Ltd., the recent winners of the coveted Most Promising Life Science Company by Nexxus, today announced the launch of their SistemTOX™ early predictive and investigative drug toxicity screening service. Based on world-leading Scottish microRNA research and technology, SistemTOX™ filters out potentially harmful compounds early in the development process, helping to save millions of pounds in costs.
People with a family history of male breast cancer perceive themselves to be at higher risk of developing the disease than do patients with a family history of female breast cancer; however those with male breast cancer in their families are less likely to know about or seek genetic testing than those with a family history of female breast cancer, according to a study led by researchers at the University of Louisville's James Graham Brown Cancer Center.
Researchers have long questioned why patients with Duchenne muscular dystrophy (DMD) tend to manage well through childhood and adolescence, yet succumb to their disease in early adulthood, or why elderly people who lose muscle strength following bed rest find it difficult or impossible to regain.
› Verified 6 days ago
| Entity Name | Sunnyside Community Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609395060 PECOS PAC ID: 1658280896 Enrollment ID: O20040227000194 |
News Archive
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced preliminary results from the EnligHTN III study, which found the company's second-generation EnligHTN™ renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. The results were presented during a hot line late-breaking clinical trial session at EuroPCR 2014.
Sistemic Ltd., the recent winners of the coveted Most Promising Life Science Company by Nexxus, today announced the launch of their SistemTOX™ early predictive and investigative drug toxicity screening service. Based on world-leading Scottish microRNA research and technology, SistemTOX™ filters out potentially harmful compounds early in the development process, helping to save millions of pounds in costs.
People with a family history of male breast cancer perceive themselves to be at higher risk of developing the disease than do patients with a family history of female breast cancer; however those with male breast cancer in their families are less likely to know about or seek genetic testing than those with a family history of female breast cancer, according to a study led by researchers at the University of Louisville's James Graham Brown Cancer Center.
Researchers have long questioned why patients with Duchenne muscular dystrophy (DMD) tend to manage well through childhood and adolescence, yet succumb to their disease in early adulthood, or why elderly people who lose muscle strength following bed rest find it difficult or impossible to regain.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Suzanne S Cleland Zamudio, MD 100 E. Jackson Avenue, Suite 102, Ellensburg, WA 98926 Ph: (509) 933-8860 | Mrs Suzanne S Cleland Zamudio, MD 100 E Jackson Ave Ste 102, Ellensburg, WA 98926-3693 Ph: (509) 933-8860 |
News Archive
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced preliminary results from the EnligHTN III study, which found the company's second-generation EnligHTN™ renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. The results were presented during a hot line late-breaking clinical trial session at EuroPCR 2014.
Sistemic Ltd., the recent winners of the coveted Most Promising Life Science Company by Nexxus, today announced the launch of their SistemTOX™ early predictive and investigative drug toxicity screening service. Based on world-leading Scottish microRNA research and technology, SistemTOX™ filters out potentially harmful compounds early in the development process, helping to save millions of pounds in costs.
People with a family history of male breast cancer perceive themselves to be at higher risk of developing the disease than do patients with a family history of female breast cancer; however those with male breast cancer in their families are less likely to know about or seek genetic testing than those with a family history of female breast cancer, according to a study led by researchers at the University of Louisville's James Graham Brown Cancer Center.
Researchers have long questioned why patients with Duchenne muscular dystrophy (DMD) tend to manage well through childhood and adolescence, yet succumb to their disease in early adulthood, or why elderly people who lose muscle strength following bed rest find it difficult or impossible to regain.
› Verified 6 days ago